JOP20210155B1 - منتج مركب نشط من {4، 6-ثنائي أمينو-2- بيريدين-3-يل] بيريميدين-5-يل} كربامات مثيل له خواص محسنة، إنتاجه وتركيبة منه - Google Patents

منتج مركب نشط من {4، 6-ثنائي أمينو-2- بيريدين-3-يل] بيريميدين-5-يل} كربامات مثيل له خواص محسنة، إنتاجه وتركيبة منه

Info

Publication number
JOP20210155B1
JOP20210155B1 JOJO/P/2021/0155A JOP20210155A JOP20210155B1 JO P20210155 B1 JOP20210155 B1 JO P20210155B1 JO P20210155 A JOP20210155 A JO P20210155A JO P20210155 B1 JOP20210155 B1 JO P20210155B1
Authority
JO
Jordan
Prior art keywords
active compound
diamino
formulation
production
product
Prior art date
Application number
JOJO/P/2021/0155A
Other languages
Arabic (ar)
English (en)
Inventor
Fey Peter
Brockob Joerg
Becker Guido
Longerich Markus
Sowa Michal
Neumann Heike
Original Assignee
Adverio Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adverio Pharma Gmbh filed Critical Adverio Pharma Gmbh
Publication of JOP20210155A1 publication Critical patent/JOP20210155A1/ar
Application granted granted Critical
Publication of JOP20210155B1 publication Critical patent/JOP20210155B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
JOJO/P/2021/0155A 2018-12-17 2021-06-16 منتج مركب نشط من {4، 6-ثنائي أمينو-2- بيريدين-3-يل] بيريميدين-5-يل} كربامات مثيل له خواص محسنة، إنتاجه وتركيبة منه JOP20210155B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18213115 2018-12-17
PCT/EP2019/085255 WO2020126983A1 (en) 2018-12-17 2019-12-16 Methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate active compound product having improved properties, production and formulation thereof

Publications (2)

Publication Number Publication Date
JOP20210155A1 JOP20210155A1 (ar) 2023-01-30
JOP20210155B1 true JOP20210155B1 (ar) 2025-10-01

Family

ID=64744472

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2021/0155A JOP20210155B1 (ar) 2018-12-17 2021-06-16 منتج مركب نشط من {4، 6-ثنائي أمينو-2- بيريدين-3-يل] بيريميدين-5-يل} كربامات مثيل له خواص محسنة، إنتاجه وتركيبة منه

Country Status (19)

Country Link
US (1) US12172996B2 (enExample)
EP (1) EP3898624A1 (enExample)
JP (1) JP7529667B2 (enExample)
KR (1) KR102872983B1 (enExample)
CN (1) CN113207290B (enExample)
AR (1) AR116912A1 (enExample)
AU (1) AU2019409269B2 (enExample)
BR (1) BR112021009122A2 (enExample)
CL (1) CL2021001580A1 (enExample)
CO (1) CO2021007668A2 (enExample)
IL (1) IL283976B2 (enExample)
JO (1) JOP20210155B1 (enExample)
MX (1) MX2021007090A (enExample)
PE (1) PE20211593A1 (enExample)
SG (1) SG11202104953VA (enExample)
TW (1) TWI830835B (enExample)
UA (1) UA129677C2 (enExample)
WO (1) WO2020126983A1 (enExample)
ZA (1) ZA202105021B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI830835B (zh) 2018-12-17 2024-02-01 德商亞德維瑞醫藥有限公司 具改善性質之{4,6-二胺基-2-[5-氟-1-(2-氟芐基)-1H-吡唑並[3,4-b]吡啶-3-基]嘧啶-5-基}胺基甲酸甲酯活性化合物產物、其製造及調配物
WO2021156223A1 (en) 2020-02-03 2021-08-12 Adverio Pharma Gmbh Nanoformulations of methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
EP3925953A1 (en) 2020-06-16 2021-12-22 Adverio Pharma GmbH Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
WO2025114276A1 (en) 2023-12-01 2025-06-05 Krka, D.D., Novo Mesto Solid oral composition comprising vericiguat

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2745813B1 (fr) 1996-03-07 1998-05-07 Rhone Poulenc Chimie Agglomerats spheriques d'acide 10-phenothiazinylpropanoique et leur procede de preparation
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
UY33041A (es) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
DK3415515T3 (da) 2009-11-27 2020-03-16 Adverio Pharma Gmbh Fremgangsmåde til fremstilling af methyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamat
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
HUE053745T2 (hu) * 2011-11-25 2021-07-28 Adverio Pharma Gmbh Helyettesített 5-fluor-1H-pirazolopiridin kristályos formában
CA2901636A1 (en) * 2013-02-21 2014-08-28 Adverio Pharma Gmbh Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate
PL2792682T3 (pl) 2013-04-19 2017-04-28 Zach System Sposób wytwarzania stałej postaci octanu abirateronu
WO2016113415A1 (en) * 2015-01-16 2016-07-21 Sandoz Ag Process for the preparation of riociguat essentially free from genotoxic impurities
WO2017025981A1 (en) * 2015-08-13 2017-02-16 Msn Laboratories Private Limited Process for the preparation of methyl 4,6-diamino-2-[l-(2-fhiorobenzvr)-lh-pyrazolo i3,4-blpvridin-3-vn-5-pyrimidinyl(methvl)carbamate and its polymorphs thereof
TWI830835B (zh) 2018-12-17 2024-02-01 德商亞德維瑞醫藥有限公司 具改善性質之{4,6-二胺基-2-[5-氟-1-(2-氟芐基)-1H-吡唑並[3,4-b]吡啶-3-基]嘧啶-5-基}胺基甲酸甲酯活性化合物產物、其製造及調配物
EP3914588A1 (en) 2019-01-22 2021-12-01 Adverio Pharma GmbH Process for manufacturing 4-(2,2,3,3-tetrafluoropropyl)morpholine
WO2021156223A1 (en) * 2020-02-03 2021-08-12 Adverio Pharma Gmbh Nanoformulations of methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
EP3925953A1 (en) * 2020-06-16 2021-12-22 Adverio Pharma GmbH Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate

Also Published As

Publication number Publication date
AU2019409269B2 (en) 2025-04-03
CO2021007668A2 (es) 2021-07-19
ZA202105021B (en) 2026-05-27
BR112021009122A2 (pt) 2021-08-10
CN113207290B (zh) 2024-04-09
US20220048907A1 (en) 2022-02-17
TW202039488A (zh) 2020-11-01
US12172996B2 (en) 2024-12-24
PE20211593A1 (es) 2021-08-18
KR20210104703A (ko) 2021-08-25
EP3898624A1 (en) 2021-10-27
MX2021007090A (es) 2021-08-11
TWI830835B (zh) 2024-02-01
AU2019409269A1 (en) 2021-06-03
IL283976B2 (en) 2025-04-01
UA129677C2 (uk) 2025-07-02
SG11202104953VA (en) 2021-06-29
JOP20210155A1 (ar) 2023-01-30
WO2020126983A1 (en) 2020-06-25
CN113207290A (zh) 2021-08-03
CA3123360A1 (en) 2020-06-25
CL2021001580A1 (es) 2021-12-03
KR102872983B1 (ko) 2025-10-17
JP2022515376A (ja) 2022-02-18
JP7529667B2 (ja) 2024-08-06
AR116912A1 (es) 2021-06-23
IL283976A (en) 2021-07-29
IL283976B1 (en) 2024-12-01

Similar Documents

Publication Publication Date Title
PH12019502286A1 (en) Process for preparing an optically active pyrimidinium compounds
MX2020005783A (es) Sialil-lactosa secada por aspersion.
PH12020551035A1 (en) Novel anthranilamides, their use as insecticide and processes for preparing the same
MX379326B (es) Procesos para la preparación de derivados de benzodiazepina
MX394621B (es) Procesos para la resolucion de los derivados de la benzodiazepina-2-ona y de la benzoazepin-2-ona
MX2024013464A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos
PH12019500731A1 (en) Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
EA202091016A1 (ru) Пиримидиновое соединение в качестве ингибитора jak киназы
MX375153B (es) Compuestos antihelminticos.
MY192425A (en) Polymorphs
PH12018502556A1 (en) Cosmetic base including amide alcohol, and cosmetic
CL2018003431A1 (es) Tratamiento de la enfermedad de parkinson.
EA202090500A1 (ru) Кристаллические формы иммуномодуляторов
PH12020550947A1 (en) Polymorphs
JOP20210157B1 (ar) تخليق 3-ميثيل-1، 2، 4-ثياديازول-5-كربوهيدرازيد أو ميثيل-d3 مُعَالَج بالديوتيريوم منه
ZA201805790B (en) Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and "azd9291 aniline" or a salt thereof
JOP20210155A1 (ar) منتج مركب نشط من {4، 6-ثنائي أمينو-2-[5-فلورو-1-(2-فلورو بنزيل)-1h-بيرازولو [3، 4-ب] بيريدين-3-يل] بيريميدين-5-يل} كربامات مثيل له خواص محسنة، إنتاجه وتركيبة منه
MX2020006370A (es) Pirazolopiridina-diamidas, su uso como insecticida y procesos para prepararlas.
EA201992117A1 (ru) Фармацевтическая комбинация, содержащая понесимод
WO2019094913A3 (en) Personal care composition
JOP20220158A1 (ar) مشتق أمينو أريل جديد مفيد كمثبط لثنائي أسيل غليسيرول أسيل ترانسفيراز 2 diacylglycerol acyltransferase 2 واستخدامه
MX381234B (es) Agente preventivo y/o terapéutico de enfermedad inmune.
EA202090393A1 (ru) Терапевтическое средство от фиброза
MX2019002234A (es) Compuesto de 1-fenil-3-carbamoil urea y uso del mismo.
MX2019006939A (es) Preparacion liquida parenteral que comprende compuesto de carbamato.